CDKN2A and pachyonychia congenita: Another study from the Netherlands by Klatte et al. in 2022 following 347 CDKN2A PGV carriers identified PC in 31 (8.9%) individuals, with 5 of these individuals having a second PC diagnosed on follow up surveillance. In this study, 16 (44.4%) of the 36 total PC diagnoses were stage I (using 8th AJCC) [63].